1) it's "liars"
2)biotech stocks often run up on anticipation and sell on the news. seems like it's taken you a while to learn that.
3)if you're relying on anything you read here on these boards as investment advice, you might want to just buy a mutual fund and watch and learn for a while.
i think it will be the opposite. OREX has been pulled up by positive developments for VVUS and ARNA. just because it's competition doesn't mean it will go down.
gold was overbought. it's correcting. the dollar only looks good because the euro looks worse. just wait until the next debt ceiling crisis at the end of the year. gold will go up again. (not a gold fan here, just have RBY on my watch list from years back and saw it was at a new yearly low).
it bounced off $26 on approval and had over half an hour to trade before it was halted. if it can't make it to $30 on approval, what kind of crack do you have to be smoking to ask about $40?
that's the point. bear raid to trigger peoples' stop losses so the raiders can get shares cheap.
VVUS didn't turn their REMS paperwork in to the FDA until early april. they needed time to read it= delay.
you are wrong. patents aren't what lets them sell the drug. it's FDA approval that does that. patents are what protects ARMN from someone else just making their own copy of the drug.
hmm. guess you can't edit posts. didn't mean to put shorts twice. they are an important part of the price decline but not important enough to be on the list twice.
they have gotten one patent (that's why it went up recently) and others are in the works. more would be better, but they already have patent protection through 2022 or something like that.
it's been going down due to 1)insider sales, 2) shorts, 3) profit-taking, overall market downturn, and 5) shorts.
there's little concern over safety or effectiveness and the FDA didn't even bother with an advisory panel. there's no reason for it not to get easy approval and analyst estimates put the value at $20+
apples and oranges.
drug with safety concerns and a CRL in its history vs. drug with absolutely no safety concerns and the FDA didn't even bother with a panel.
"this junk" already has a patent. http://www.retirementplanningzone.com/amarin-jumps-on-new-patent-amrn-pfe-trgt-gale-bpax-knsy/979 more are not necessary, but would be icing on the cake.
holding a short position, i meant. sorry- didn't mean to be unclear. there's no reason this stock shouldn't get approval and be $20+
bash all you want. one patent, more to come. fish oil so safe they didn't even bother with an advisory panel. there's been plenty of money to be made on this stock over the last year- short and long. but if you think it's smart holding this through the PDUFA, you're gonna get burned.
that's hilarious. the bio runup method came about by observing the way biotechs behaved. bio stocks were doing this same thing long before there was a "bio runup" website.
there's no "they" and no "take". this company is a one-trick pony competing with 3 other ponies who know the same trick. fair value is a buck or two if that.